Isobutylshikonin

Name: Isobutylshikonin
Brand: MedChemExpress
SKU: HY-N2592
Rating: 4.5 (0 reviews)

製品番号: HY-N2592 純度: 99.93%: Data Sheet SDS COA 取扱説明書
FAQs
Technical Support

Isobutylshikonin is a kind of shikonin pigments found in hairy root culture of Lithospermum canescens. Isobutylshikonin decreases cell viability induces marked changes in JA-4 cells with nuclear condensation and swelling in the presence of LPS (HY-D1056).

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

Isobutylshikonin 構造式

CAS 番号 : 52438-12-7

容量	価格（税別）	在庫状況	数量
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 220	在庫あり	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 220	在庫あり	Estimated Time of Arrival: December 31
Solid
5 mg	$200	在庫あり	Estimated Time of Arrival: December 31
10 mg	$300	在庫あり	Estimated Time of Arrival: December 31
25 mg	$515	在庫あり	Estimated Time of Arrival: December 31
50 mg		お問い合わせ
100 mg		お問い合わせ

or バルクお問い合わせ

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 0 publication(s) in Google Scholar

おすすめ

•関連スクリーニングライブラリ:

•関連小分子:

•関連タンパク質:

生物活性
純度とドキュメンテーション
参考文献
カスタマーレビュー

製品説明

Cellular Effect

Cell Line	Type	Value	Description	References
A-375	IC₅₀	1.71 μM Compound: SK-5	Antiproliferative activity against human A-375 cells assessed as inhibition of cell proliferation measured after 3 days by MTT assay Antiproliferative activity against human A-375 cells assessed as inhibition of cell proliferation measured after 3 days by MTT assay	[PMID: 39129245]
BTI-TN-5B1-4	IC₅₀	57.5 μM Compound: 2	Inhibition of human ACAT2 expressed in Hi5 cells Inhibition of human ACAT2 expressed in Hi5 cells	[PMID: 17157006]
Ca9-22	IC₅₀	1.8 μM Compound: Isobutyrylshikonin	Cytotoxicity against human Ca9-22 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human Ca9-22 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 35367708]
Ca9-22	IC₅₀	1.98 μM Compound: Isobutyrylshikonin	Cytotoxicity against human Ca9-22 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human Ca9-22 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 35367708]
HCT-116	IC₅₀	0.34 μM Compound: 13	Cytotoxicity against MDR1 Pgp under-expressing human HCT116 cells after 24 hrs by MTT assay Cytotoxicity against MDR1 Pgp under-expressing human HCT116 cells after 24 hrs by MTT assay	[PMID: 17949858]
HCT-116	IC₅₀	1.73 μM Compound: SK-5	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 3 days by MTT assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 3 days by MTT assay	[PMID: 39129245]
HeLa	IC₅₀	84 μM Compound: 6	Inhibitory activity against DNA topoisomerase-1 obtained from Hela cells Inhibitory activity against DNA topoisomerase-1 obtained from Hela cells	[PMID: 7699697]
HepG2	IC₅₀	0.22 μM Compound: 13	Cytotoxicity against MDR1 Pgp overexpressing human HepG2 cells after 24 hrs by MTT assay Cytotoxicity against MDR1 Pgp overexpressing human HepG2 cells after 24 hrs by MTT assay	[PMID: 17949858]
HepG2	IC₅₀	8.73 μM Compound: SK-5	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation measured after 3 days by MTT assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation measured after 3 days by MTT assay	[PMID: 39129245]
U-937	IC₅₀	0.05 μM Compound: 123	Cytotoxicity against human U-937 cells assessed as reduction in cell viability incubated for 72 hrs by resazurin assay Cytotoxicity against human U-937 cells assessed as reduction in cell viability incubated for 72 hrs by resazurin assay	[PMID: 38458106]

体外実験

Isobutylshikonin (0-20 μM, 4 h) decreases cell viability of JA-4 cells in the presence of LPS (HY-D1056) (100ng/mL) but alone has no effect on macrophage viability^[1].

Isobutylshikonin (5 μM, 4 h) induces marked changes in JA-4 cells with nuclear condensation and swelling in the presence of LPS (100ng/mL), but alone does not cause morphological changes of the macrophages^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

358.39

分子式

C₂₀H₂₂O₆

CAS 番号

52438-12-7

Appearance

Solid

Color

Brown to black

SMILES

O=C1C2=C(O)C=CC(O)=C2C(C=C1[C@@H](C/C=C(C)/C)OC(C(C)C)=O)=O

Structure Classification

Initial Source

輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

溶剤 & 溶解度

体外:

DMSO : 10 mg/mL (27.90 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.7903 mL	13.9513 mL	27.9026 mL
5 mM	0.5581 mL	2.7903 mL	5.5805 mL
10 mM	0.2790 mL	1.3951 mL	2.7903 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）

体積 _（開始）

濃度 _（終了）

体積 _（終了）

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1 mg/mL (2.79 mM); Clear solution

This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

純度とドキュメンテーション

純度: 99.93%

Select Batch:

データシート (276 KB) SDS (252 KB)

COA (255 KB) HNMR (117 KB) RP-HPLC (369 KB)

取扱説明書 (2659 KB)

参考文献

[1]. Koike A, et al. Simultaneous Addition of Shikonin and Its Derivatives with Lipopolysaccharide Induces Rapid Macrophage Death. Biol Pharm Bull. 2016;39(6):969-76. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.7903 mL	13.9513 mL	27.9026 mL	69.7564 mL
	5 mM	0.5581 mL	2.7903 mL	5.5805 mL	13.9513 mL
	10 mM	0.2790 mL	1.3951 mL	2.7903 mL	6.9756 mL
	15 mM	0.1860 mL	0.9301 mL	1.8602 mL	4.6504 mL
	20 mM	0.1395 mL	0.6976 mL	1.3951 mL	3.4878 mL
	25 mM	0.1116 mL	0.5581 mL	1.1161 mL	2.7903 mL